A comprehensive package combining C-reactive protein and serum amyloid A point-of-care testing reduced antibiotic prescribing by 61% for acute respiratory tract infections in Chinese village clinics. The cluster randomised controlled trial published in The Lancet Regional Health – Western Pacific involved 76 village clinics across rural China and demonstrated the potential for biomarker-guided treatment to combat antibiotic overuse.
Antibiotic prescribing rates before and after intervention
Percentage of acute respiratory infection patients prescribed antibiotics, by clinic type
rate (all clinics)
final rate
final rate
Source: The Lancet Regional Health – Western Pacific, 2026 | Georgian Medical Journal News
Biomarker testing transforms rural antibiotic prescribing
The trial enrolled 4,982 patients presenting with acute respiratory tract infections across 76 village clinics in Anhui Province between September 2019 and September 2021. Intervention clinics received a comprehensive package including point-of-care testing devices measuring C-reactive protein and serum amyloid A levels, clinical decision support software, and training for healthcare providers according to WHO antimicrobial stewardship guidelines.
The results demonstrated a dramatic reduction in antibiotic prescribing rates from a baseline of 87.6% to 32.5% in intervention clinics, compared to minimal change in control clinics (87.6% to 83.1%). Dr. Chris Fang, lead researcher at Duke Kunshan University’s Global Health Research Center, reported these findings represent the largest reduction in antibiotic overprescribing achieved through point-of-care testing in a rural primary care setting.
Patient safety maintained despite reduced prescribing
Safety outcomes remained comparable between intervention and control groups, with no significant differences in hospitalization rates, return visits, or adverse events. The CDC estimates that 30% of antibiotic prescriptions in outpatient settings are unnecessary, making these safety findings particularly significant for scaling similar interventions.
Healthcare providers in intervention clinics reported high satisfaction with the point-of-care testing technology, with 94% stating they would recommend the system to colleagues. The testing provided objective biomarker data within 3-5 minutes, enabling more confident treatment decisions for both bacterial and viral respiratory infections according to clinical protocols published in clinical practice guidelines.
Implementation challenges remain for scaling
Despite promising results, researchers identified several barriers to widespread implementation including device costs, training requirements, and integration with existing clinic workflows. The total intervention cost per clinic was approximately $2,800 USD, which may limit adoption in resource-constrained settings without appropriate financing mechanisms or government support.
The study authors noted that future implementation efforts should examine health system contexts and identify cost-effective strategies for scaling point-of-care testing in primary care settings. Current antimicrobial resistance patterns suggest urgent need for such interventions, particularly in countries where antibiotic overuse remains prevalent in respiratory tract infection management.
The comprehensive package reduced antibiotic prescribing by 61% while maintaining patient safety, representing the largest documented reduction in antibiotic overprescribing through point-of-care testing in rural primary care.
— Dr. Chris Fang, Duke Kunshan University Global Health Research Center (The Lancet Regional Health – Western Pacific, 2026)
Key takeaways
- Point-of-care CRP and SAA testing reduced antibiotic prescribing from 87.6% to 32.5% for acute respiratory infections
- No significant differences in safety outcomes including hospitalizations or return visits between intervention and control groups
- 94% of healthcare providers would recommend the testing system to colleagues, indicating high acceptability
- Implementation costs of $2,800 per clinic may require policy support for widespread adoption
Frequently asked questions
What biomarkers were measured in the point-of-care testing?
The testing measured C-reactive protein (CRP) and serum amyloid A (SAA) levels, which help distinguish bacterial from viral respiratory infections. Results were available within 3-5 minutes to guide antibiotic prescribing decisions.
Were patients harmed by the reduced antibiotic prescribing?
No significant differences in safety outcomes were observed between intervention and control groups. Hospitalization rates, return visits, and adverse events remained comparable, suggesting the reduction in prescribing was appropriate.
Can this approach be implemented in other healthcare settings?
The researchers noted that implementation requires examination of specific health system contexts and identification of cost-effective scaling strategies. The $2,800 per clinic cost may necessitate policy support or financing mechanisms for broader adoption.
The findings provide compelling evidence for biomarker-guided antibiotic prescribing in primary care settings, particularly as global health authorities emphasize antimicrobial stewardship. Future research should focus on developing sustainable financing models and streamlined implementation protocols to enable widespread adoption of point-of-care testing for respiratory tract infections.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
